SALT LAKE CITY, Oct. 18, 2012 (GLOBE NEWSWIRE) -- BioFire Diagnostics, Inc. today announced that it has appointed Herm Rosenman to its Board of Directors and Chairman of the Audit Committee. Mr. Rosenman was Senior Vice President and Chief Financial Officer of Gen-Probe, Inc. from 2001 until its recent acquisition by Hologic, Inc.
"We are excited to add Mr. Rosenman to the BioFire Board of Directors. His appointment reflects our strategy to establish a world-class organization with a goal of changing the treatment and diagnostic paradigm of infectious disease. His direct experience in healthcare and with public companies will add to the depth and breadth of the Board and we look forward to his leadership as head of our Audit Committee," said Carl Wittwer, MD, PhD, Chairman of the Board of BioFire Diagnostics.
Kirk Ririe, Chief Executive Officer of BioFire, added, "Herm's addition complements our ground breaking technical team with truly extraordinary financial and managerial acumen. We believe his experience combined with FilmArray's growth opportunity will help advance BioFire's momentum in the clinical diagnostics arena."
Herm Rosenman said, "I am excited to join the Board of BioFire and to bring my operational and financial expertise to the Company at this vital juncture of its development and growth. I have been impressed with the Company's technology, particularly FilmArray, one of the most innovative, paradigm changing instruments in the diagnostic space."
Prior to joining Gen-Probe, Mr. Rosenman served as Chief Executive Officer of two Nasdaq-listed companies, served on the boards of multiple healthcare companies and was a partner at Coopers & Lybrand (now PricewaterhouseCoopers). Mr. Rosenman, a CPA, received a B.B.A. in finance and accounting from Pace University and an M.B.A. in finance from the Wharton School of the University of Pennsylvania.
About BioFire Diagnostics, Inc.
BioFire Diagnostics, Inc., formerly Idaho Technology, Inc., is a privately held clinical diagnostics company based in Salt Lake City, Utah. The Company manufactures and distributes the FilmArray Respiratory Panel, which operates on the user-friendly FilmArray system, to hospital-based clinical laboratories across the U.S. and EU. With the FilmArray RP, BioFire provides the only FDA-cleared clinical diagnostic test for eight of the 20 organisms in its panel. In addition, BioFire continues to broaden its FilmArray test menu, and is currently developing, among others, a blood culture ID panel, a gastrointestinal panel, and a meningitis panel.
BioFire holds over 70 patents related to polymerase chain reaction (PCR), and it has used its extensive patent portfolio to successfully market nearly 200 products to the clinical, research, and military markets. BioFire customers include the Department of Health and Human Services, the Department of Defense, state and local law enforcement, and researchers and medical technicians across a spectrum of fields and industries.
For further information, please visit www.BioFireDx.com.
CONTACT: BioFire Diagnostics, Inc. Eric Gorrell (investor relations) General Counsel 801-736-6354 x803 Eric@biofiredx.com The Ruth Group (on behalf of BioFire Diagnostics) Victoria Aguiar (media) 646-536-7013 email@example.com
Source:BioFire Diagnostics, Inc.